Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors

Condition(s) studied

Investigational drug(s) / intervention(s)

MT027 cells suspension: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells

Study summary

MT027 is an off-the-shelf, allogeneic chimeric antigen receptor T cell (UCAR-T) injection prepared from healthy donor T cells targeting B7-H3. It is a next-generation, ready-to-use CAR-T product that can be used immediately and promptly for patients to solve the problem of unmet medical needs for a large number of patients who have a demand for CAR-T therapy but cannot receive it due to the common reasons of long production cycle, insufficient production capacity, and incompatibility of patients' T cells with the production conditions. In addition, the expected medical cost of allogeneic CAR-T cells is significantly lower, which can greatly alleviate the economic burden on patients.

MT027 is prepared by expressing a chimeric antigen receptor (CAR) targeting B7H3 on gene-edited T cells through gene modification technology. MT027 products targeting the B7H3 target developed by Moxing Biotech avoid the potential graft-versus-host disease (GvHD) and host anti-graft reaction (HvGR) caused by the interaction between exogenous T cells and the patient's immune system, and have shown good safety and efficacy in recurrent high-grade glioma in the initial phase.

Eligibility

Primary outcome measure(s)

• Adverse Events (AE) and Serious Adverse Events (SAE) — through study completion, an average of 1 year
• Dose Limiting Toxicity (DLT) — 28 days
• Graft-versus-host Disease (GvHD) — through study completion, an average of 1 year
• Cytokine Release Syndrome (CRS) — through study completion, an average of 1 year
• Immune effector cell-associated neurotoxicity syndrome (ICANs) — through study completion, an average of 1 year

Trial sites (1)

More Suzhou Maximum Bio-tech Co., Ltd. trials in China

Other trials for the same condition